글로벌 우울증 검진 시장 – 2030년까지의 산업 동향 및 예측

우울증 검진 시장 분석 및 규모

우울증 검사라고도 알려진 우울증 검진은 주로 환자가 임상적으로 우울증인지 알아내는 데 사용됩니다. 흔한 질병의 일종이지만 우울증은 일반적인 슬픔의 감정과는 다르며 사람의 사고 과정과 행동에도 영향을 미칠 수 있습니다.

전 세계적으로 정신 질환의 유병률이 증가하는 것은 글로벌 우울증 검진 시장의 성장과 수요를 촉진하는 중요한 요인 중 하나입니다. 또한, 고급 진단 및 치료 방법을 쉽게 이용할 수 있고 정신 질환 및 관련 장애가 있는 환자 수가 증가하는 것도 2023년에서 2030년까지의 예측 기간 동안 글로벌 시장 성장에 기여하고 있습니다. 또한, 연구 활동에 대한 자금이 빠르게 증가하고 의료 분야가 빠르게 변화함에 따라 시장 성장이 촉진되고 있습니다. 나아가, 1인당 가처분 소득이 증가하는 것도 글로벌 우울증 검진 시장의 성장을 촉진하는 중요한 요인 중 하나입니다. 정신 질환 및 관련 장애가 있는 환자 수가 증가함에 따라 예측 기간 동안 산업이 크게 성장할 것입니다.

Data Bridge Market Research는 글로벌 우울증 검진 시장이 2022년에 10,624.91백만 달러로 평가되었으며 2030년까지 15,829.87백만 달러에 도달할 것으로 추산되며 2023년에서 2030년까지의 예측 기간 동안 5.11%의 CAGR로 성장할 것으로 예상됩니다. Data Bridge Market Research 팀이 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함됩니다. 시장 가치, 성장률, 세분화, 지리적 범위 및 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 심층적인 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크가 포함됩니다.

우울증 검진 시장 범위 및 세분화

시장 정의

The market includes both traditional screening methods, such as questionnaires and interviews, and technologically advanced solutions, such as digital platforms, mobile applications, and wearable device that enable convenient remote screening. It includes various screening tools, techniques, and services to identify and assess symptoms of depression so that health professionals can make an accurate diagnosis and develop an appropriate treatment plan increase. The global depression screening market serves individuals seeking mental health assessment, healthcare providers, mental health organizations, and other stakeholders involved in the diagnosis and management of depression. It plays a crucial role in early identification, intervention, and prevention of depression, aiming to improve mental health outcomes and enhance overall well-being.

Global Depression Screening Market Dynamics

Drivers

• Increasing Prevalence of Depression

The rising prevalence of depression across the globe is the primary driver for the growth of the global depression screening market. Stress, lifestyle changes, and social pressure have contributed to the increased prevalence of depression, creating a need for effective screening methods, which is expected to drive market growth.

• Rising Awareness and Mental Health Advocacy

Awareness of mental health issues, including depression, is growing around the world. An increasing number of organizations, government initiatives, and celebrity advocacy have reduced the stigma associated with mental health and encouraged more people to seek testing and treatment options, which is expected to drive the market growth

• Technological Advancements in Screening Tools

The growing advancement in technology has led to the development of innovative screening tools and solutions for depression. Digital platforms, mobile apps, and mobile devices equipped with depression screening features have made it easier and easier to assess people's mental health status, which has fuelled market growth.

Opportunities

• Growing Adoption of Telehealth and Remote Screening

The increasing adoption of telehealth services provides an opportunity for remote depression screening. Virtual consultations and digital screening tools enable individuals to access screening services from the comfort of their homes, eliminating geographical barriers and improving access to mental health care.

• Increasing Technological Advancements
• Continued integrating artificial intelligence technologies, such as machine learning algorithms, into depression screening tools offers opportunities for more accurate and efficient assessments. Exam platforms powered by AI can analyze large data sets, identify patterns and deliver personalized exam results, improving the overall exam process, which helps to create an opportunity for the market growth.

Restraint

• Limited Awareness and Stigma in Certain Regions

Although mental health awareness is growing worldwide, there are still areas where awareness and stigma around mental health issues, such as depression, are still limited. A lack of awareness may hinder the adoption of depression control services in these regions, thereby hindering market growth.

Challenges

• Lack of Quality Assurance and Standardization

Ensuring the quality and standardization of depression screening tools and methods across regions and health facilities can be challenging. To maintain the reliability of depression screening programs, it is important to develop uniform screening guidelines and protocols and establish criteria for accuracy and reliability.

This global depression screening market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global depression screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2021, the company received breakthrough device designation from the FDA for its digital diagnostic and therapeutic platform for autism spectrum disorder (ASD) and comorbid behavioral health conditions like depression.
• In September 2020, Pear Therapeutics received FDA clearance for its digital therapeutic called reSET-O. This prescription digital therapeutic is designed to treat opioid use disorder with a co-occurring moderate-to-severe depressive disorder.

Global Depression Screening Market Scope

The global depression screening market is segmented into five notable segments based on disease type, diagnosis, treatment, and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

• Anxiety
• Mood disorders
• Depression
• Bipolar disorders
• Psychotic disorders
• Eating disorders
• Others

Diagnosis

• Psychological test
• Lab tests
• Depression screening tests
• Others

Treatment

• Medication
• Brain-stimulation treatments
• Deep brain stimulation

End User

• Hospitals and clinics
• Medical research centers
• Academic institutes
• Others

Global Depression Screening Market Regional Analysis/Insights

The global depression screening market is analyzed, and market size insights and trends are provided based on disease type, diagnosis, treatment, and end user.

The countries covered in this market report are the U.S., Canada, and Mexico in North America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa(MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to dominate the global depression screening market due to the increasing research in depression screening and development.

The U.S. is expected to dominate the North America region due to the rise in healthcare expenditure and the high prevalence of dental diseases seen in the country. Germany is expected to dominate Europe due to the increasing technology and reliability of healthcare services, which also deliver infotainment services. The demand in this region is projected to be driven by a rise in dental diseases with the growing integration of healthcare data with portable devices. China is expected to dominate the Asia-Pacific region due to exponential awareness of cancer diagnostics and consultancy services in the country.

The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges due to large or scarce competition from local and domestic brands and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global depression screening market also provides you with a detailed market analysis for every country’s growth in healthcare expenditure for capital equipment, installed base of different kind of products for global depression screening market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2015-2020.

Competitive Landscape and Global Depression Screening Market Share Analysis

글로벌 우울증 검진 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 프로그램 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

글로벌 우울증 검진 시장에서 활동하는 주요 기업은 다음과 같습니다.

• 존슨앤존슨서비스 주식회사(미국)
• 아스트라제네카(영국)
• 브리스톨-마이어스 스퀴브 회사(미국)
• 릴리(미국)
• F. 호프만-라 로슈 유한회사(스위스)
• 노바티스 AG(스위스)
• 오츠카 홀딩스 주식회사(일본)
• 파이저 주식회사(미국)
• GSK plc (영국)
• Janssen Global Services LLC(벨기에)
• 메이지 홀딩스 주식회사(일본)
• 애벗(미국)
• 재즈 파마슈티컬스 주식회사(아일랜드)
• AbbVie Inc.(미국)
• 3M(미국)
• 아카디아 파마슈티컬스 주식회사(미국)
• 메드트로닉(아일랜드)
• Bausch Health Companies Inc. (캐나다)
• 머크 KGaA(독일)

SKU-35662